Targets of Treatment in Chronic Inflammatory Bowel Diseases

List of principle authors. Preface. <STRONG>Defining Targets of Treatment by</STRONG> <STRONG>Analysis of Gut Inflammation. 1.</STRONG> State of the Art Lecture: Theories of IBD aetiology from the 1930s to the 1960s; <EM>D.B. Sachar.</EM> <STRONG>I: Defining</STRONG> <STRONG>Targets by Understanding Aetiopathogenesis of Gut Inflammation. 2.</STRONG> Development of novel drugs for IBD based on molecular targets; <EM>S.</EM> <EM>Schreiber.</EM> <STRONG>3.</STRONG> On the role of innate immunity during mucosal defence and intestinal infections: Are there new therapeutic targets for intervention? <EM>S. Bauer.</EM> <STRONG>4.</STRONG> Enteric bacteria: Innocent bystanders, therapeutic targets or vehicles for mucosal delivery of therapeutic molecules? <EM>R.B. Sartor.</EM> <STRONG>II: Tools for Therapeutic Development. 5.</STRONG> Do animal models always give the right direction for therapy? <EM>C.O. Elson,</EM> <EM>et al.</EM> <STRONG>6.</STRONG> Are cell lines and cultures a good way to develop therapeutic approaches? <EM>G. Rogler.</EM> <STRONG>7.</STRONG> Characterization of intestinal barrier function: A putative target for therapeutical modification; <EM>M.</EM> <EM>Gehring, J.-D. Schulzke.</EM> <STRONG>III: Alternative Concepts New Targets in the</STRONG> <STRONG>Making. 8.</STRONG> The adipose tissue as a source of proinflammatory signals in Crohn's disease? <EM>J.-F. Colombel, et al.</EM> <STRONG>9.</STRONG> Intraluminal targets in Crohn's disease: The possible role of bile acids; <EM>A.F. Hofmann.</EM> <STRONG>10.</STRONG> Therapeutic targets in rheumatoid arthritis: Is there a lesson to be learned for gastroenterologists? <EM>U. Müller-Ladner.</EM> <STRONG>V: General</STRONG> <STRONG>Targets. 11.</STRONG> Interstitial lung diseases and inflammatory bowel diseases: Pathophysiological parallels and differences; <EM>J.</EM> <EM>Müller-Quernheim.</EM> <STRONG>12.</STRONG> A functional genomics approach to study wound repair: The roles of activin and S100A8/S100A9 in the healing process; <EM>I.S. Thorey, et al.</EM> <STRONG>13.</STRONG> Neuroendocrine-immune interactions: A novel therapeutic approach? <EM>S.M. Collins.</EM> <STRONG>Aims of Treatment in Daily</STRONG> <STRONG>Practice. 14.</STRONG> State of the Art Lecture: Evolution of treatment from the 1930s to the end of the 1980s; <EM>P. Riis.</EM> <STRONG>15.</STRONG> Extraintestinal manifestations Important target of treatment or just an expression of disease activity? <EM>F. Tavarela-Veloso.</EM> <STRONG>16.</STRONG> What do patients want? Defining treatment goals from the other side; <EM>J. Minchew.</EM> <STRONG>17.</STRONG> Measuring health-related quality of life: Fad, fantasy or fruitful exercise? <EM>E.J. Irvine.</EM> <STRONG>VI: Specific Targets. 18.</STRONG> Specific targets Diarrhea; <EM>W. Kruis, et al.</EM> <STRONG>19.</STRONG> Abdominal pain as a therapeutic target in inflammatory bowel disease; <EM>H.J.F. Hodgson.</EM> <STRONG>20.</STRONG> Strictures in IBD Are there differential indications for surgery or endoscopic dilation? <EM>G.van Assche, et al.</EM> <STRONG>21.</STRONG> Spectrum of inflammatory bowel diseases related arthropathy: are there differential treatment options? <EM>M.de</EM> <EM>Vos.</EM> <STRONG>VII: Special Problems. 22.</STRONG> Magnetic resonance imaging (MRI) in patients with IBD: A new method to assess disease activity; <EM>S.</EM> <EM>Feuerbach, et al.</EM> <STRONG>23.</STRONG> Cancer prevention in inflammatory bowel disease as a treatment goal; <EM>A. Ekbom.</EM> <STRONG>VIII: Quality of Care. 24.</STRONG> The impact of age and social environment on therapeutic concepts; <EM>C.</EM> <EM>Gasché.</EM> <STRONG>25.</STRONG> Avoiding side effects: A therapeutic goal? <EM>W.J.</EM> <EM>Sandborn.</EM> Index.